Search Results - oid-nchhstp-dte

3 Results

Sort By:

Diagnostic Antigens for the Identification of Latent Tuberculosis Infection

CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine...

Published: 7/25/2024 | Inventor(s): Manon Deslauriers, Kristin Birkness, Peter King, Bernard Beall, Frederick Quinn

Keywords(s): ANTIGENS, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DEXXXX, diagnostic, DXXXXX, Granuloma, Human, IA3XXX, Identification, Latent, Methods, Model, OID-NCHHSTP-DTE, TUBERCULOSIS, VAXXXX, Vitro, VJXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, YBXXXX, YDXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Geriatrics, TherapeuticArea > Immunology, Application > Consumer Products, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Diagnostics, ResearchProducts > Antibodies, Application > Vaccines, Application > Occupational Safety and Health

Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy

CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and...

Published: 7/25/2024 | Inventor(s): Manon Deslauriers, Kristin Birkness, Peter King, Bernard Beall, Frederick Quinn

Keywords(s): AC4XXX, AC5XXX, ACXXXX, ANTIGENS, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DEXXXX, diagnostic, DXXXXX, Granuloma, Human, IA3XXX, Identification, Latent, Methods, Model, OID-NCHHSTP-DTE, TUBERCULOSIS, Vitro, VJXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XHXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Consumer Products, Application > Occupational Safety and Health, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics

Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis

This CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest widely variable effectiveness for the BCG vaccine and that BCG administration has very limited success against prevention...

Published: 7/25/2024 | Inventor(s): Bonnie Plikaytis, Thomas Shinnick, Rama Amara, Mani Cheruvu, Suraj Sable

Keywords(s): Alaine, ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC1XXX, DC4XXX, DCXXXX, DXXXXX, Identification, Mucosal, MYCOBACTERIUM, OID-NCHHSTP-DTE, PROLINE, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, Rich, TUBERCULOSIS, Vaccine, VACCINE DEVELOPMENT, VJXXXX, VPXXXX, WIXXXX, WJXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, Application > Research Materials, TherapeuticArea > Endocrinology, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Dental, TherapeuticArea > Ophthalmology, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment